Feb 27, 2026
Why the Right CRO Partner Accelerates Your Path to Clinical Trials The decision to outsource drug development is not just about capacity or convenience. For startups advancing a first candidate into clinical trials and biotech companies managing multi-asset pipelines,...
Feb 17, 2026
A contract research organization (CRO) is a company that provides outsourced research, development, and regulatory services to pharmaceutical and biotech companies. CROs support drug development at every stage, from early preclinical work through clinical trials and...
Feb 10, 2026
Speed Without Shortcuts Our Molecule-to-Clinic process typically shaves months off the process used by traditional vendors. We achieve this through the efficient use of the latest scientific methodologies along with coordinated project management and parallel...Gyan Mishra received his PhD (University of Missouri Kansas City) in pharmaceutics before completing post-doctoral studies at Oregon State University. His academic credentials are complemented by his practical experience leading teams of scientists and engineers at notable organizations including ThermoFisher Scientific. He successfully led formulation and process development scientists for commercialization of many pharmaceutical products. Gyan joined FreeThink in early 2025 where he leads the Engineering and Formulation Sciences group.
Chetan Shende brings over 18 years of pharmaceutical analytical science experience to FreeThink where he serves as Associate Director of the Analytical Sciences group. Holding an MS in Analytical Chemistry from the University of South Florida, with deep expertise in HPLC, GC, and Raman spectroscopy for API and drug product analysis, Chetan plays a key role in driving the quality and efficiency of FreeThink’s laboratory operations.
Patrick Kelleher received his BS (Stonehill College) and PhD (Yale University) in physical chemistry before completing post-doctoral studies at the University of Virginia. His graduate and post-doctoral research focused on developing spectroscopic and mass-spectrometric techniques for the structural elucidation of small molecules. Patrick joined FreeThink in 2020 where he leads the Physical Sciences group in designing and executing rapid, material-sparing stability studies using FreeThink’s ASAPprime® software.
Dave received his BS from Springfield College and has over 20 years of pharmaceutical industry experience, including supply chain management, clinical development operations, and global clinical trial management. He founded and led the drug product development consulting firm Verdure Bay before joining FreeThink in 2018 where he leads global business development.
Alisa received her BA (Wesleyan University) and PhD (Albert Einstein College of Medicine) in cell biology. She completed post-doctoral studies (Yale University) before spending 24 years at Boehringer Ingelheim (as a Senior Research Fellow), championing discovery and development of biological and small molecule drug candidates. In 2015, Alisa joined FreeThink where she manages the customer portfolio of projects.
Mark received his BA (Washington University) and MBA (University of Rochester). After working on Wall Street for 17 years (Credit Suisse First Boston, Merrill Lynch) as an equity analyst, he helped found FreeThink in 2011 and currently heads the software division and manages company finances.
After receiving his BS (UCLA) and PhD (UC Berkeley) in physical-organic chemistry, Ken completed post-doctoral studies (Columbia University) before spending 12 years at Polaroid as a distinguished scientist, then 13 years at Pfizer as a Research Fellow, and has successfully invented and commercialized many imaging and pharmaceutical products. He is an American Association of Pharmaceutical Scientists (AAPS) Fellow, the author of over 75 publications and patents, and a speaker at numerous international conferences. Ken helped found FreeThink in 2011 and serves as a technical expert and provides overall company leadership.
Pharmacist and toxicologist, member of the board of directors of the Brazilian Society of Toxicology (SBTox) and CEO of Spektra Consultancy. She worked in the pharmaceutical industry in Brazil actively participating in the scientific and regulatory development of the areas of analytical development and toxicological evaluations focused on impurities assessments. More than 15 years of experience in developing stability-indicating methods and toxicological assessment of impurities in drug substances and drug products (degradation products, mutagenic impurities/nitrosamines, elemental impurities, extractable and leachable) using in silico tools and integrated risk assessment. She currently works as a consultant at Spektra Consultancy in the area of impurity assessment in compliance with ANVISA and ICH regulations. Spektra is also the representative of FreeThink Technologies in Latin America.
After receiving his B.S. (UCLA) and Ph.D. (UC Berkeley) in physical-organic chemistry, Kenneth Waterman completed post-doctoral studies (Columbia University) before spending 12 years at Polaroid (as a distinguished scientist), then 13 years at Pfizer (as a Research Fellow). He has successfully invented and commercialized a number of products and is the author of over 75 publications. He was made an AAPS Fellow in 2011 the same year he started FreeThink Technologies.
A firm specializing in solutions to the most difficult stability, impurity, analytical, solid-state, and formulation issues. Retiring from Lilly in 2015, he brings 30 years of experience in the pharmaceutical industry to his consulting firm, with a demonstrated track record of innovation and problem-solving. He obtained his Ph.D. in Organic Chemistry in 1989 from Vanderbilt University, joining Lilly that same year.
Dr. Baertschi has organized/chaired numerous scientific conferences / symposia on stress testing, stability, photostability, and impurities, and has published extensively in these areas, including two editions of a book on pharmaceutical stress testing / drug degradation. Dr. Baertschi is a member of the American Chemical Society, the American Association of Pharmaceutical Scientists (AAPS), is a Fellow of the AAPS (since 2007).
He has a B.Sc. in Chemistry and a D.Phil in the application of magnetic resonance spectroscopy (ESR and NMR) to determine the mechanisms and kinetics of organic oxidation reactions. He has over 25 years of experience in analytical chemistry in the pharmaceutical industry, working in areas ranging from inhalation to dissolution, and has authored numerous regulatory submissions. In recent years, Garry focuses on pharmaceutical stability and has helped to develop, refine, and apply accelerated studies for the prediction of long-term stability performance. Garry has authored numerous scientific papers and recently co-authored a book on “Accelerated Predictive Stability.” Garry’s role at Pfizer also includes troubleshooting pharmaceutical product problems, understanding causes of poor stability, and improving product design.
Dr. Hemingway graduated from the University of Hull in 2012 with a Ph.D. in Chemistry under the supervision of Steve Archibald, developing tumor-targeted therapeutics. The multidisciplinary project allowed her to develop skills in organic, analytical, coordination chemistry, and cell culture. After two and a half years working as a research scientist for a chemical manufacturer, Rachel joined Lhasa Limited. She has been part of the science team at Lhasa for over 8 years, working almost exclusively on the software program Zeneth. As a principal scientist, Rachel leads a team of scientists who develop the Zeneth knowledge base while influencing the software’s strategy and direction. Her interests lie in developing software tools to address knowledge gaps and support decision-making in the degradation community. She has co-authored five journal articles (one in preparation) and four book chapters.
